This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nagashima, A. Articles by Nomoto, K. Search for Related Content PubMed PubMed Citation Articles by Nagashima, A. Articles by Nomoto, K.

Establishment and Characterization of High- and Low-Metastatic Clones Derived from a Methylcholanthrene-induced Rat Fibrosarcoma¹

Department of Surgery II, Faculty of Medicine [A. N., K. Y., H. N., T. F., K. I.], and the Department of Immunology, Medical Institute of Bioregulation [K. N.], Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812, Japan

High- (Cl-33H) and low- (Cl-35L) metastatic clones were established from a methylcholanthrene-induced rat fibrosarcoma (FMQ-100). The modal chromosome numbers of the two clones were different. These clones grew in in vitro culture, showing similar growth rate and saturation density. However, in in vivo experiments, Cl-33H exhibited a higher tumor growth rate, tumorigenicity, spontaneous metastatic potential, and experimental metastatic potential than did Cl-35L. Alveolar macrophages obtained from normal syngeneic rats stimulated growth of these clones in vitro, as assessed by [³H]thymidine uptake. Moreover, this effect was greater on Cl-33H than Cl-35L. The growth-promoting effect of macrophages was also observed under the in vitro condition of lack of direct contact between macrophages and tumor cells. These results suggested the possibility that alveolar macrophage-derived growth-promoting factors play some role in the development of pulmonary metastasis in this tumor system, and the difference of susceptibility to the growth-promoting factors might be one of the causes of the different metastatic potentials of Cl-33H and Cl-35L.

¹ Supported in part by Grants-in-aid for Cancer Research (59010003) from the Ministry of Education, Science, and Culture.

² To whom requests for reprints should be addressed.

Received 11/27/84. Revised 1/28/86. Revised 5/ 1/86. Accepted 5/23/86.

This article has been cited by other articles:

				P. M. Petre, F. A. Baciewicz Jr, S. Tigan, and J. R. Spears Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model J. Thorac. Cardiovasc. Surg., January 1, 2003; 125(1): 85 - 95. [Abstract] [Full Text] [PDF]

				A. Abolhoda, A. Brooks, S. Nawata, Y. Kaneda, H. Cheng, and M. E. Burt Isolated Lung Perfusion With Doxorubicin Prolongs Survival in a Rodent Model of Pulmonary Metastases Ann. Thorac. Surg., July 1, 1997; 64(1): 181 - 184. [Abstract] [Full Text]

				H.-Y. Wang, H. M. Ross, B. Ng, and M. E. Burt Establishment of an Experimental Intrapulmonary Tumor Nodule Model Ann. Thorac. Surg., July 1, 1997; 64(1): 216 - 219. [Abstract] [Full Text]

				H.-Y. Wang, B. Ng, D. Blumberg, J. L. Port, S. N. Hochwald, and M. E. Burt Pulmonary Artery Perfusion of Doxorubicin With Blood Flow Occlusion: Pharmacokinetics and Treatment in a Metastatic Sarcoma Model Ann. Thorac. Surg., November 1, 1995; 60(5): 1390 - 1394. [Abstract] [Full Text]

				B. Weksler, J. Lenert, B. Ng, and M. Burt Isolated single lung perfusion with doxorubicin is effective in eradicating soft tissue sarcoma lung metastases in a rat model J. Thorac. Cardiovasc. Surg., January 1, 1994; 107(1): 50 - 54. [Abstract] [Full Text]